7356-95-8Relevant articles and documents
Urease inhibitory kinetics, molecular docking, SAR and ADME studies of imine analogues
Imran, Aqeel,Iqbal, Jamshed,Naz, Asia,Qazi, Syeda Uroos
, p. 3512 - 3520 (2022/02/21)
A series of synthesized imine derivatives (3a-m), including thio-semicarbazone, semicarbazone, thiazole and oxazole functional moieties, were examined for in vitro urease inhibition activity. Among all the analogues, 3b, 3k and 3f were the most potent against urease, exhibiting IC50 values of 1.52 ± 0.026, 2.20 ± 0.018 and 2.94 ± 0.058 μM, respectively. Docking studies were performed for the potent inhibitors to demonstrate their binding interactions with urease. Kinetic studies were also performed to assess the mode of interaction of the most potent analogue with urease. Moreover, an in silico ADME study was performed to evaluate the drug likeness of the compounds. All the analogues showed favorable ADME profiles.
Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
-
, (2008/06/13)
This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R1, R21, R22 and R23 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl; or R22 and R23, together with the N, form a heterocycle; A1 and A2 are independently aryl, heteroaryl, saturated or partially unsaturated carbocycle or saturated or partially unsaturated heterocycle, any of which is optionally substituted; X is one or O, S, NR24, CR25R26, C(O), NR24C(O), C(O)NR24, SO, SO2 or a covalent bond; where R24, R25 and R26 are independently hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, aryl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or carboxyalkyl. The invention also is directed to the use of carbocycle and heterocycle substituted semicarbazones and thiosemicarbazones for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), for the treatment and prevention of otoneurotoxicity and eye diseases involving glutamate toxicity and for the treatment, prevention or amelioration of pain, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy and urinary incontinence.
